Related Experiment Videos
Systemic amiloride inhibits experimentally induced neovascularization.
R L Avery1, T B Connor, M Farazdaghi
1Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore, MD 21205.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|October 11, 1990
Summary
Amiloride, an inhibitor of urokinase-type plasminogen activator, significantly reduced corneal neovascularization by 55% in rabbits. This finding suggests amiloride
Area of Science:
- Ophthalmology
- Pharmacology
- Vascular Biology
Background:
- Neovascularization is a key process in various ocular diseases.
- Urokinase-type plasminogen activator (uPA) plays a role in neovascularization.
- Amiloride is known to inhibit uPA activity.
Purpose of the Study:
- To investigate the potential of amiloride as an inhibitor of neovascularization.
- To evaluate the effect of amiloride on experimentally induced corneal neovascularization in rabbits.
Main Methods:
- Corneal neovascularization was induced in rabbits using prostaglandin E1 pellets.
- Animals received daily intraperitoneal injections of amiloride (30 mg) or saline for 5 days.
- Corneal neovascularization was quantified using photographic evaluation.
Main Results:
- Amiloride treatment was well tolerated in rabbits.
- The area of induced corneal neovascularization was reduced by 55% in the amiloride group compared to controls.
- Amiloride demonstrated a significant inhibitory effect on neovascularization.
Conclusions:
- Amiloride effectively inhibits experimental corneal neovascularization.
- Amiloride and similar compounds show promise for managing neovascularization.
- Further research into amiloride's therapeutic potential in neovascular diseases is warranted.